Company Name: Abbot Laboratories (Pakistan) Ltd
Ticker: ABOT
Reporting period: Three months ended March 31, 2026
Reporting basis: Unaudited, company-only condensed interim financial statements; amounts are in Pakistani rupees unless stated otherwise.
Verdict: better margins outweighed a slow top line, but cash conversion weakened
Abbott Pakistan began 2026 with only modest sales growth, yet converted that revenue into substantially more gross and net profit. Net sales increased 2.1% to PKR 17.70 billion, gross profit rose 14.7% to PKR 6.70 billion, and profit after tax advanced 21.3% to PKR 1.94 billion. The decisive improvement was gross margin, which widened to 37.8% from 33.7% as reported cost of sales declined despite higher revenue. These amounts and the April 27, 2026 board approval are set out in the company’s official first-quarter report.
The quality of that profit improvement was mixed. Management attributed the margin expansion mainly to cost optimization and efficiency measures, but operations did not convert accounting earnings into cash. Inventory, advances and receivables absorbed funds, while income-tax payments nearly doubled. Net operating cash flow therefore swung to a PKR 574 million outflow from a PKR 804 million inflow. The quarter shows a stronger income statement alongside a more demanding working-capital cycle.
Reporting basis and what the filing covers
The analysis uses Abbott Laboratories (Pakistan) Limited’s unaudited standalone statements for January through March 2026, compared with January through March 2025. Balance-sheet comparisons are against audited December 31, 2025 figures. The PSX issuer page records the financial-results announcement on April 27 and transmission of the full quarterly report on April 29, 2026.
The company reports four operating segments: pharmaceutical, nutritional, diagnostic and others. Segment sales are shown net of returns, trade discounts, sales tax and excise duty. Because these are company-only accounts, they do not consolidate the global Abbott group. The holding company owned 76.26 million shares at March 31, 2026, and Abbott Laboratories in the United States remained the ultimate parent.
Quarterly comparison: current period, prior period, change and interpretation
The percentage changes below are AlphaGen calculations from the company-reported amounts in the March 2026 interim statements. They are not management guidance.
- Net sales: PKR 17.70 billion versus PKR 17.35 billion; up 2.1%. Interpretation: growth was positive but subdued, consistent with management’s description of slower patient traffic and a muted respiratory-tract-infection and flu season.
- Gross profit: PKR 6.70 billion versus PKR 5.84 billion; up 14.7%. Gross margin: 37.8% versus 33.7%, an improvement of about 4.1 percentage points. Interpretation: cost efficiency, not top-line acceleration, was the main earnings lever.
- Selling and distribution expense: PKR 2.92 billion versus PKR 2.72 billion; up 7.2%. Interpretation: commercial spending rose faster than sales, partly absorbing the gross-margin benefit.
- Administrative expense: PKR 380 million versus PKR 303 million; up 25.5%. Interpretation: overhead growth was significant, although the disclosure does not provide enough detail to assign the increase to one cause.
- Profit before tax: PKR 3.29 billion versus PKR 2.75 billion; up 19.6%. Pre-tax margin increased to 18.6% from 15.9%. Interpretation: the wider gross margin more than offset higher operating expenses and finance costs.
- Profit after tax: PKR 1.94 billion versus PKR 1.60 billion; up 21.3%. Net margin rose to 11.0% from 9.2%, while basic and diluted EPS increased to PKR 19.82 from PKR 16.34.
- Cash generated from operations before income taxes and other long-term movements: PKR 1.06 billion versus PKR 1.72 billion; down 38.1%. Net operating cash flow: negative PKR 574 million versus positive PKR 804 million.
- Closing cash and bank balances: PKR 12.47 billion versus PKR 13.34 billion at December 2025; down 6.5%. Interpretation: the company remained liquid, but working-capital funding, tax, investment and financing outflows reduced cash by PKR 864 million during the quarter.
Revenue mix and segment economics
Pharmaceuticals supplied the growth and most of the margin improvement
Pharmaceutical net sales increased 5.7% to PKR 12.33 billion and represented about 70% of company net sales. Gross profit grew 23.1% to PKR 4.70 billion, lifting the segment’s gross margin to 38.1% from 32.7%. Its segment result rose 39.9% to PKR 2.56 billion. Management said established brands sustained performance. The segment table in the official report supports the reported sales, cost and expense bridge.
Economically, pharmaceuticals carried the quarter because a relatively small sales increase was paired with lower segment cost of sales. The filing attributes the wider company and pharmaceutical margins to optimization and efficiency measures, but it does not quantify price, volume, product mix or procurement effects separately. Any more precise causal split would therefore be inference rather than a reported fact.
Nutrition protected gross margin but lost sales and segment profit
Nutritional net sales declined 5.3% to PKR 3.74 billion. Gross profit nevertheless increased 3.7% to PKR 1.72 billion, and gross margin widened to 45.9% from 41.9%. Selling and distribution expense rose sharply, however, and the segment result fell 13.0% to PKR 762 million. This is a useful warning against reading gross margin in isolation: commercial costs can prevent product-margin improvement from reaching operating profit.
Diagnostics was stable in revenue but weaker at gross-profit level
Diagnostic net sales were nearly flat at PKR 1.22 billion, down 0.4%. Gross profit fell 29.6% to PKR 154 million and gross margin contracted to 12.6% from 17.8%. Lower selling expenses allowed the segment result to rise to PKR 32 million from PKR 24 million, but the underlying product economics weakened. The smaller “others” segment generated PKR 419 million of net sales, down 17.1%, and a PKR 48 million result, down 46.7%.
Profitability below the segment line
Total segment result increased 20.6% to PKR 3.40 billion. Other income fell to PKR 229 million from PKR 260 million, while other charges were nearly flat at PKR 320 million. Finance cost increased to PKR 18 million from PKR 4 million but remained small relative to operating profit. The detailed reconciliation appears in the segment and profit notes.
The mix within other income changed. Interest income on savings accounts rose to PKR 189 million from PKR 112 million, while gains on disposal of property, plant and equipment dropped to PKR 15 million from PKR 97 million. Exchange losses declined to PKR 16 million from PKR 45 million. These movements were favorable in part, but the lower disposal gain kept total other income below the prior period.
The reported tax charge was PKR 1.35 billion versus PKR 1.13 billion. The effective rate remained close to 41% in both periods, so tax did not explain the change in net margin. Rather, the improvement came mainly from the operating margin. No associate income, revaluation gain or major exceptional item appears in the profit statement for this quarter.
Balance sheet and cash conversion
Total assets rose 7.2% from December 2025 to PKR 50.17 billion, while equity increased 6.5% to PKR 33.69 billion. Current assets of PKR 34.39 billion covered current liabilities of PKR 14.76 billion by about 2.3 times. The balance sheet in the quarterly filing also shows no conventional bank borrowing; lease liabilities totaled PKR 477 million.
Liquidity was strong in absolute terms, but the quarter required considerably more operating funding. Inventory increased 21.6% from December to PKR 15.14 billion, trade receivables rose 6.8% to PKR 3.01 billion, and loans and advances climbed to PKR 1.34 billion from PKR 399 million. Trade and other payables rose 13.1% to PKR 13.79 billion and partly financed those increases.
The cash-flow reconciliation makes the pressure clearer. Working-capital changes absorbed PKR 2.67 billion, compared with PKR 1.37 billion a year earlier. Inventory alone used PKR 2.69 billion and loans and advances used PKR 941 million; the PKR 1.59 billion increase in trade and other payables was the major offset. Income taxes paid rose to PKR 1.64 billion from PKR 879 million, taking net operating cash flow below zero despite higher profit.
Investing activities used a net PKR 244 million, including PKR 460 million of additions to property, plant and equipment, partly offset by interest receipts and asset-disposal proceeds. Financing used PKR 46 million, mostly lease rentals and finance costs. Capital-expenditure commitments were PKR 713 million, letters-of-credit commitments were PKR 1.44 billion, and bank guarantees were PKR 502 million at quarter-end.
The company disclosed PKR 7.60 billion of short-term banking facilities, with up to PKR 4.29 billion available for running finance or short-term loans, but said none of that borrowing capacity was used at March 31. This provides a liquidity backstop, yet rising inventory and advances still deserve attention because persistent working-capital absorption can eventually reduce financial flexibility.
Operational dependencies, management outlook and risks
Related-party purchases of stock-in-trade increased to PKR 4.36 billion from PKR 3.83 billion, while sales to group companies rose to PKR 364 million from PKR 233 million. This confirms meaningful group-company sourcing and trading flows, but the filing does not disclose enough information to quantify imported content, supplier concentration or currency denomination. Readers should avoid assuming a precise foreign-exchange sensitivity from these totals alone.
Management described the regulatory, fiscal and macroeconomic environment as fluid. It welcomed changes for nonessential medicines outside the National Essential Medicines List, while arguing that essential-drug pricing reviews, hardship cases and low-priced-drug issues still require a robust process. This is a management position, not an independent regulatory forecast, but it identifies pricing policy as an important earnings and product-availability variable.
Management also warned that geopolitical tensions, oil prices, inflation and foreign-exchange conditions could disrupt operations or demand. The economic links are plausible: imported or group-sourced inputs can become more expensive when the rupee weakens, oil affects freight and packaging costs, and inflation can constrain patient spending. The filing does not quantify each sensitivity, so these should be monitored as risk channels rather than treated as forecast profit impacts.
Dividends and corporate actions
The April 27 PSX financial-results letter presents the approved quarterly accounts but contains no dividend recommendation, bonus issue, rights issue or other entitlement. The statement of changes in equity likewise records no owner distribution during the quarter. The cash-flow statement shows only PKR 82 thousand of dividends paid, which relates to settlement of outstanding amounts rather than a new material distribution.
What to monitor next
- Sales quality: whether pharmaceutical growth remains ahead of the nutrition and diagnostics slowdown, and whether management begins disclosing clearer price, volume and mix drivers.
- Gross-margin durability: whether the roughly four-percentage-point company margin gain persists after the initial optimization benefits and through changes in raw-material, freight and currency costs.
- Commercial and administrative discipline: selling and administrative expenses both grew faster than revenue, so continued cost escalation could narrow the benefit from product-level efficiency.
- Working capital: inventory, advances, receivables and payables should be read together. A return to positive operating cash flow would be stronger evidence that accounting profit is converting into cash.
- Segment health: pharmaceutical margin carried the result; nutrition’s lower segment profit and diagnostics’ weaker gross margin are the main internal counterweights.
- Tax and liquidity: the effective tax rate remained high, while cash declined despite a debt-light balance sheet. Tax payments, capital spending and unused borrowing capacity will shape future flexibility.
AlphaGen model readings
These four displayed readings are AlphaGen model outputs, not company-reported financial figures. They should be interpreted alongside the official accounts and not as investment advice.
- Alpha QoQ Score: 59.23
- TTM Performance Score: 96.22
- 3Y Business Perf Score: 95.92
- Sector Leadership Score: 56.2988
Bottom line
Abbott Pakistan’s first quarter was an income-statement improvement led by pharmaceutical gross margin and supported by stable taxation relative to pre-tax profit. Sales growth was modest, but the company earned more on each rupee of revenue and lifted EPS by more than one-fifth.
The unresolved issue is cash conversion. A debt-light balance sheet and PKR 12.47 billion cash position provide resilience, yet the inventory and advances build, higher tax payments and rising operating expenses mean the result should not be judged on profit growth alone. The next reports will be stronger if margin gains persist while working capital normalizes and nutrition and diagnostics stabilize.
Sources
- Abbott Laboratories (Pakistan) Limited — unaudited first-quarter report for the three months ended March 31, 2026, transmitted April 29, 2026
- Abbott Laboratories (Pakistan) Limited — PSX financial-results filing approved April 27, 2026
- Pakistan Stock Exchange — ABOT issuer page and announcement history